Eikon Therapeutics ( NASDAQ:EIKN – Get Free Report ) was upgraded by analysts at Mizuho to a “strong-buy” rating in a note issued to investors on Wednesday, Zacks reports.
EIKN has been the topic of several other research reports. Wedbush decreased their price target on shares of Eikon Therapeutics from $5.00 to $4.00 and set an “underperform” rating on the stock in a research report on Friday, August 14th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Eikon Therapeutics in a research report on Friday, August 21st. Finally, Weiss Ratings raised Eikon Therapeutics from a “sell (e-)” rating to a “sell (e)” rating in a research note on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Eikon Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $25.00.
Get Eikon Therapeutics alerts: Check Out Our Latest Research Report on Eikon Therapeutics
Eikon Therapeutics Trading Up 1.1%
Shares of Eikon Therapeutics stock opened at $8.60 on Wednesday. Eikon ...